These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 85106)

  • 1. Stimulation of prostacyclin release from vessel wall by Bay g 6575, an antithrombotic compound.
    Vermylen J; Chamone DA; Verstraete M
    Lancet; 1979 Mar; 1(8115):518-20. PubMed ID: 85106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of arterial thrombosis and platelet function by nafazatrom.
    Buchanan MR; Blajchman M; Hirsh J
    Thromb Res; 1982 Oct; 28(2):157-70. PubMed ID: 6758186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin.
    Moncada S; Korbut R
    Lancet; 1978 Jun; 1(8077):1286-9. PubMed ID: 78050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of platelet aggregation in vivo. IX. Effect of nafazatrom on in vivo platelet aggregation and spontaneous tumor metastasis.
    Ambrus JL; Ambrus CM; Gastpar H; Williams P
    J Med; 1982; 13(1-2):35-47. PubMed ID: 6288824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antithrombotic activity of BAY g 6575.
    Seuter F; Busse WD; Meng K; Hoffmeister F; Möller E; Horstmann H
    Arzneimittelforschung; 1979; 29(1):54-9. PubMed ID: 375948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced release of a 'prostacyclin-like' substance from aortic strips of spontaneously hypertensive rats.
    Botha JH; Leary WP; Asmal AC
    Prostaglandins; 1980 Feb; 19(2):285-9. PubMed ID: 6992226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased vascular prostacyclin (PGI2) in diabetic rats. Stimulation of PGI2 release in normal and diabetic rats by the antithrombotic compound Bay g 6575.
    Carreras LO; Chamone DA; Klerckx P; Vermylen J
    Thromb Res; 1980 Aug 15-Sep 1; 19(4-5):663-70. PubMed ID: 7003804
    [No Abstract]   [Full Text] [Related]  

  • 8. Vascular substances that modulate blood-to-vessel interactions.
    Ts'ao CH
    Artery; 1979 Mar; 5(3):246-61. PubMed ID: 393210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suloctidil: a novel inhibitor of platelet aggregation in human beings.
    de Gaetano G; Miragliotta G; Roncucci R; Lansen J; Lambelin G
    Thromb Res; 1976 Mar; 8(3):361-71. PubMed ID: 1265708
    [No Abstract]   [Full Text] [Related]  

  • 10. 2,3-diphosphoglycerate: a physiological inhibitor of platelet aggregation.
    Iatridis SG; Iatridis PG; Markidou SG; Ragatz BH
    Science; 1975 Jan; 187(4173):259-61. PubMed ID: 1111100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostacyclin is the major prostaglandin released from the isolated perfused rabbit and rat heart.
    de Deckere EA; Nugteren DH; Ten Hoor F
    Nature; 1977 Jul; 268(5616):160-3. PubMed ID: 339097
    [No Abstract]   [Full Text] [Related]  

  • 12. A study of the stimulation of human venous prostacyclin synthesis by dipyridamole.
    Jackson CA; Greaves M; Preston FE
    Thromb Res; 1982 Sep; 27(5):563-73. PubMed ID: 6758183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic properties of water-soluble carbon monoxide-releasing molecules.
    Kramkowski K; Leszczynska A; Mogielnicki A; Chlopicki S; Fedorowicz A; Grochal E; Mann B; Brzoska T; Urano T; Motterlini R; Buczko W
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2149-57. PubMed ID: 22772756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of prostacyclin in vascular tissue.
    Moncada S; Vane JR
    Fed Proc; 1979 Jan; 38(1):66-71. PubMed ID: 215463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of furosemide on prostacyclin-like antiaggregatory release from vessel wall and renal cortex.
    Weithmann KU
    Pharmacol Res Commun; 1982 May; 14(5):391-9. PubMed ID: 7051051
    [No Abstract]   [Full Text] [Related]  

  • 16. Antithrombotic activity of a polydeoxyribonucleotidic substance extracted from mammalian organs: a possible link with prostacyclin.
    Niada R; Mantovani M; Prino G; Pescador R; Berti F; Omini C; Folco GC
    Thromb Res; 1981 Aug; 23(3):233-46. PubMed ID: 7029778
    [No Abstract]   [Full Text] [Related]  

  • 17. Enhanced prostacyclin production by dipyridamole in man.
    Neri Serneri GG; Masotti G; Poggesi L; Galanti G; Morettini A
    Eur J Clin Pharmacol; 1981; 21(1):9-15. PubMed ID: 7037426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of astaxanthin on blood coagulation, fibrinolysis and platelet aggregation in hyperlipidemic rats.
    Deng ZY; Shan WG; Wang SF; Hu MM; Chen Y
    Pharm Biol; 2017 Dec; 55(1):663-672. PubMed ID: 27951728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Almitrine increases plasma fibrinolytic activity through the release of prostacyclin from lungs into circulation.
    Korbut R; Byrska-Danek A; Gryglewski RJ
    Pharmacol Res Commun; 1982 Nov; 14(10):959-65. PubMed ID: 6760210
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.